Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system

Magdolna Kovács, Imre Mezö, J. Seprődi, V. Csernus, István Teplán, Béla Flerkó

Research output: Article

18 Citations (Scopus)

Abstract

A powerful GnRH antagonist: [Ac-D-Trp1,3,D-Cpa2,D-Lys6,D-Ala10]-GnRH (MI-1544) and a superactive GnRH agonist: [D-Phe6,desGly10]-GnRH(1-9)EA (OVURELIN) were used in long-term administration to compare their effects on the inhibition of ovulation, LH and progesterone (P) release, LH content of pituitaries as well as on the recovery period. Both analogs showed 100% inhibitory effects on ovulation in very low doses during the daily treatment for 21 days. The antagonist prevented LH release already after the first injection, decreased the serum P level to 40%, and increased the LH content of the pituitary up to 180%, inhibiting only the release but not the synthesis of LH. The agonist showed marked LH-releasing effects on the first day of the treatment, which were reduced to 12% on the 7th day. Serum P concentration was dropped to 68% by the end of the treatment. No change was found in the LH content of pituitaries in the group treated with the agonist. Ovaries showed polifollicular pictures in the antagonist-treated group, and persistent corpora lutea were seen in the ovaries from the agonist-treated group. Regular estrous cycles returned 13-15 days after ceasing the treatment with the antagonist and 3-5 days after ceasing the treatment with the agonist. No edema-inducing effect was observed after the injections of the antagonist in doses of 100 times higher than the single antiovulatory dose.

Original languageEnglish
Pages (from-to)925-931
Number of pages7
JournalPeptides
Volume10
Issue number5
DOIs
Publication statusPublished - 1989

Fingerprint

Gonads
Gonadotropin-Releasing Hormone
Ovary
Ovulation Inhibition
Therapeutics
Injections
Estrous Cycle
Corpus Luteum
Progesterone
Ovulation
Serum
Edema
Recovery

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system. / Kovács, Magdolna; Mezö, Imre; Seprődi, J.; Csernus, V.; Teplán, István; Flerkó, Béla.

In: Peptides, Vol. 10, No. 5, 1989, p. 925-931.

Research output: Article

Kovács, Magdolna ; Mezö, Imre ; Seprődi, J. ; Csernus, V. ; Teplán, István ; Flerkó, Béla. / Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system. In: Peptides. 1989 ; Vol. 10, No. 5. pp. 925-931.
@article{b2dfbdfa24494ab88f73446db124d822,
title = "Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system",
abstract = "A powerful GnRH antagonist: [Ac-D-Trp1,3,D-Cpa2,D-Lys6,D-Ala10]-GnRH (MI-1544) and a superactive GnRH agonist: [D-Phe6,desGly10]-GnRH(1-9)EA (OVURELIN) were used in long-term administration to compare their effects on the inhibition of ovulation, LH and progesterone (P) release, LH content of pituitaries as well as on the recovery period. Both analogs showed 100{\%} inhibitory effects on ovulation in very low doses during the daily treatment for 21 days. The antagonist prevented LH release already after the first injection, decreased the serum P level to 40{\%}, and increased the LH content of the pituitary up to 180{\%}, inhibiting only the release but not the synthesis of LH. The agonist showed marked LH-releasing effects on the first day of the treatment, which were reduced to 12{\%} on the 7th day. Serum P concentration was dropped to 68{\%} by the end of the treatment. No change was found in the LH content of pituitaries in the group treated with the agonist. Ovaries showed polifollicular pictures in the antagonist-treated group, and persistent corpora lutea were seen in the ovaries from the agonist-treated group. Regular estrous cycles returned 13-15 days after ceasing the treatment with the antagonist and 3-5 days after ceasing the treatment with the agonist. No edema-inducing effect was observed after the injections of the antagonist in doses of 100 times higher than the single antiovulatory dose.",
keywords = "GnRH agonist, GnRH antagonist, Long-term effect, Pituitary LH, Serum progesterone",
author = "Magdolna Kov{\'a}cs and Imre Mez{\"o} and J. Seprődi and V. Csernus and Istv{\'a}n Tepl{\'a}n and B{\'e}la Flerk{\'o}",
year = "1989",
doi = "10.1016/0196-9781(89)90170-8",
language = "English",
volume = "10",
pages = "925--931",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system

AU - Kovács, Magdolna

AU - Mezö, Imre

AU - Seprődi, J.

AU - Csernus, V.

AU - Teplán, István

AU - Flerkó, Béla

PY - 1989

Y1 - 1989

N2 - A powerful GnRH antagonist: [Ac-D-Trp1,3,D-Cpa2,D-Lys6,D-Ala10]-GnRH (MI-1544) and a superactive GnRH agonist: [D-Phe6,desGly10]-GnRH(1-9)EA (OVURELIN) were used in long-term administration to compare their effects on the inhibition of ovulation, LH and progesterone (P) release, LH content of pituitaries as well as on the recovery period. Both analogs showed 100% inhibitory effects on ovulation in very low doses during the daily treatment for 21 days. The antagonist prevented LH release already after the first injection, decreased the serum P level to 40%, and increased the LH content of the pituitary up to 180%, inhibiting only the release but not the synthesis of LH. The agonist showed marked LH-releasing effects on the first day of the treatment, which were reduced to 12% on the 7th day. Serum P concentration was dropped to 68% by the end of the treatment. No change was found in the LH content of pituitaries in the group treated with the agonist. Ovaries showed polifollicular pictures in the antagonist-treated group, and persistent corpora lutea were seen in the ovaries from the agonist-treated group. Regular estrous cycles returned 13-15 days after ceasing the treatment with the antagonist and 3-5 days after ceasing the treatment with the agonist. No edema-inducing effect was observed after the injections of the antagonist in doses of 100 times higher than the single antiovulatory dose.

AB - A powerful GnRH antagonist: [Ac-D-Trp1,3,D-Cpa2,D-Lys6,D-Ala10]-GnRH (MI-1544) and a superactive GnRH agonist: [D-Phe6,desGly10]-GnRH(1-9)EA (OVURELIN) were used in long-term administration to compare their effects on the inhibition of ovulation, LH and progesterone (P) release, LH content of pituitaries as well as on the recovery period. Both analogs showed 100% inhibitory effects on ovulation in very low doses during the daily treatment for 21 days. The antagonist prevented LH release already after the first injection, decreased the serum P level to 40%, and increased the LH content of the pituitary up to 180%, inhibiting only the release but not the synthesis of LH. The agonist showed marked LH-releasing effects on the first day of the treatment, which were reduced to 12% on the 7th day. Serum P concentration was dropped to 68% by the end of the treatment. No change was found in the LH content of pituitaries in the group treated with the agonist. Ovaries showed polifollicular pictures in the antagonist-treated group, and persistent corpora lutea were seen in the ovaries from the agonist-treated group. Regular estrous cycles returned 13-15 days after ceasing the treatment with the antagonist and 3-5 days after ceasing the treatment with the agonist. No edema-inducing effect was observed after the injections of the antagonist in doses of 100 times higher than the single antiovulatory dose.

KW - GnRH agonist

KW - GnRH antagonist

KW - Long-term effect

KW - Pituitary LH

KW - Serum progesterone

UR - http://www.scopus.com/inward/record.url?scp=0024377399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024377399&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(89)90170-8

DO - 10.1016/0196-9781(89)90170-8

M3 - Article

C2 - 2691997

AN - SCOPUS:0024377399

VL - 10

SP - 925

EP - 931

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 5

ER -